| Time to engage in measurement uncertainty |
|
|
|
In the ongoing "War of Words" in the Lab, it's time to hear another voice. Dr. Dietmar Stockl, an expert from across the Atlantic, provides us with a detailed essay explaining how measurement uncertainty can be useful to the laboratory - and even co-exist with Total Error.
September 2008 Dietmar Stöckl
|
Laboratory approach using available data
|
| Analytical specificity | Cross reactivity data, but no indication of their relevance for patients’ specimens. |
| Interference | Interference limit 10% (concentrations given for lipids, etc). No interference with common drugs. |
| Linearity | Limit 10% |
| Recovery | Limit 10% |
| Method comparison | Acceptable slope: 0.9 - 1.1 |
| Limit of detection (LoD) | 0.1 nmol/L |
| Quantitation limit (CV = 20%) | 0.4 nmol/L |
| Reportable range range (from LoD to calibration maximum) | 0.1 - 60 nmol/L |
| Expected values |
Male: 10 - 28 nmol/L |
| Stability data calibrator and reagent lots | Some decline during maximum recommended time (no limits given). |
| Lot-to-lot criteria calibrators and reagents | No information available. |

Scientific information
Consultation of the scientific literature revealed the risk of considerable sample related effects, in particular, for females (7). The incidence of antibody interference seems to be low (8, 9), while interferences due to cross-reactivity seem to be more common (10 - 12). Interferences to consider are dehydroepiandrostenedione sulphate and testosterone conjugates.
Laboratory approach for estimating measurement uncertainty using all above information
The laboratory could verify the imprecision data, but decided to modify the uncertainty estimates of the manufacturer in the following way:
- the uncertainty “point” estimates were converted into intervals and one range was added;
- the estimate in the low range was expanded for sample related effects and considering the quantitation limit of the assay (total effect: factor of 2);
- the estimate in the low-medium range was expanded by sample-related effects (in the order of the total imprecision) and the imprecision was interpolated;
- an uncertainty of 5% was added in all ranges to account for recovery and linearity;
- the lower end of the working range was increased to 0.25 nmol/L (relative big difference between the LoD and the quantitation limit).
- A risk analysis was done for interferences and a policy was written.
- The trueness problem was discussed with the manufacturer and their rationale was accepted.
- The laboratory keeps the following uncertainty estimates in its files.

Beyond GUM
The long-term internal quality control data indicated a somewhat high lot-to-lot variation (u = 10%). The laboratory made total error calculations and simulations by introduction of biases. It found that biases of 10% changed the results “to be acted upon” by 50%. While this was deemed too high, no solution could be found. The laboratory increased its quality assurance efforts and introduced a quality control rule with an increased power.

Limitations of GUM
As outlined above, bias is not covered by the GUM calculations but needs to be corrected. However, the treatment of bias (existing or input in total error models) is vital to the laboratory. For example, to investigate the effect of reagent batch-to-batch variations on patient data. Figure 1 below shows a test with a batch-to-batch CVbb of 10% (= 10 at a value of 100) and a within-batch CVwb of 5%. It was created by simulating 20 random numbers with a SD of 10 and a mean of 100. Then, for each of the 20 values (batch means are indicated by bars), 20 random numbers were simulated with a SD of 5. The figure would represent quality control data obtained with a batch lasting 20 days and doing 1 QC sample a day. Further, it is assumed that the mean of the stable process is known to be 100.

According to GUM, 2 possibilities exist. If the observation time is extended over all 20 batches, the biases of the individual batches become random and the total CVtot becomes 11.2%. The laboratory may decide to keep in its files that the process has an uncertainty of 11.2%, without considering the bias introduced when changing reagent batches. This, however, would give a false impression about the test performance, because the bias in each reagent batch may have a profound influence on diagnostic decisions (13). If the observation time is 2 batches, considerable systematic effects would be seen from time to time (batch 2, for example). This is the reasoning why GUM deprecates the distinction between “random” and “systematic”: it may depend on the observation time. According to GUM, one would correct the second batch giving a mean of 120 (bias = 20%). The laboratory, however, is usually unable to correct for batch-to-batch variations. Nevertheless, it needs to know the effect of a 20% bias on the patient results. If such a bias would increase the false positives by 50%, for example, it may require the manufacturer to tighten his batch-to-batch variations. Also, the laboratory needs a model that accounts for bias in order to select the appropriate quality control rules. Such a model, for example, is the total error approach used in the Westgard software products.
Contrary to the GUM philosophy, it is vital for the laboratory to distinguish between random and systematic effects. When systematic effects have to be taken into account, other concepts must be used for describing measurement variability, such as the total error concept. Thus, in my opinion, the different concepts are complementary and not contradictory. GUM alone, however, is unsufficient for managing real-world situations in the clinical laboratory.

A note on Quality control
The above example shows a dilemma of quality control: shall the laboratory use a CV of 11.2% or a CV of 5% as input value for the QC process? If a CV of 11.2% is chosen, typical QC rules seldom will give alarms. If a CV of 5% is chosen, typical QC rules will indicate problems regularly. But then, what to do? Currently, there is no easy answer to the problem. Obviously, for QC purposes, one could change the target value of the quality control sample, however, this changes nothing for the bias of the patient samples.
In the future, it would be desirable that manufacturers keep the between-batch variation in the same order as the within-batch variation. For comparison, Figure 2 shows a QC chart with CVbb = CVwb = 5%. The total CVtot is 7.1%.

References
- ISO/IEC Guide 98:1995. Guide to the expression of uncertainty in measurement (GUM). International Organization for Standardization: Geneva, 1995.
- ISO/IEC Guide 99:2007. International vocabulary of metrology – Basic and general concepts and associated terms (VIM). International Organization for Standardization: Geneva, 2007.
- JCGM 200:2008. International vocabulary of metrology – Basic and general concepts and associated terms (VIM). International Bureau of Weights and Measures (BIPM); Joint Committee for Guides in Metrology (JCGM): Paris, 2008 (electronic document freely available at: http://www.bipm.org/en/publications/guides/vim.html).
- Kringle RO. Statistical Procedures. In Burtis CA, Ashwood ER [eds]. Tietz Textbook of Clinical Chemistry, 2nd edition, Chapter 12, pages 419-422. Philadelphia: Saunders, 1994.
- Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol 2007;2:162-74.
- Paulson WD, Roberts WL, Lurie AA, Koch DD, Butch AW, Aguanno JJ. Wide variation in serum anion gap measurements by chemistry analyzers. Am J Clin Pathol 1998;110:735-42.
- Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, Boudou P. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003;49:1381-95.
- Kuwahara A, Kamada M, Irahara M, Naka O, Yamashita T, Aono T. Autoantibody against testosterone in a woman with hypergonadotropic hypogonadism. J Clin Endocrinol Metab 1998;83:14-6.
- Torjesen PA, Bjøro T. Antibodies against [125I] testosterone in patient's serum: a problem for the laboratory and the patient. Clin Chem 1996;42:2047-8.
- Middle JG. Dehydroepiandrostenedione sulphate interferes in many direct immunoassays for testosterone. Ann Clin Biochem 2007;44:173-7.
- Heald AH, Butterworth A, Kane JW, Borzomato J, Taylor NF, Layton T, Kilpatrick ES, Rudenski A. Investigation into possible causes of interference in serum testosterone measurement in women. Ann Clin Biochem 2006;43:189-95.
- Stanczyk FZ, Cho MM, Endres DB, Morrison JL, Patel S, Paulson RJ. Limitations of direct estradiol and testosterone immunoassay kits. Steroids 2003;68:1173-8.
- Thienpont LM. Calculation of measurement uncertainty-Why bias should be treated separately. Clin Chem 2008;54:1587.
Internet resources
- http://physics.nist.gov/cuu/Uncertainty/index.html
- http://physics.nist.gov/Pubs/guidelines/
- http://www.measurementuncertainty.org/mu/guide/index.html
| < Prev | Next > |
|---|
Member Login
What's New

Guest Essay
- Biologic Variation Database, the 2012 update
- Managing Quality in Networked Laboratories
- Dietmar Stockl, QC Reality Check, Part Five
- Saving money by applying TEa and Six Sigma for internal QC.
- Dietmar Stockl, QC Reality Check, Part Four
- Dietmar Stockl, QC Reality Check, Part Three
- Dietmar Stockl, QC Reality Check, Parts One and Two
- Interpretation of Differences in Serial Troponin Results
- Upgrading Quality Control in Molecular Diagnostics
- Stability Testing and CLSI EP25-A
- Biologic Variation Database, the 2010 update
- Rilibak: Quality Goals the German way
- Are "Scientific Statements" the Scientific Truth?
- Sysmex Perspective on Sigma-metrics
- Time to engage in measurement uncertainty
- Quality of Proficiency Testing
- When Quality depends on the company you keep
- Waiting for the FDA
- Quality Requirements for Veterinary Labs
- Understanding Quality










